Evidence map›Paper›PMID 24141556›Full record

ArticleLung2014

Stratification of malignant pleural mesothelioma prognosis using recursive partitioning analysis.

Hidekazu Suzuki, Kazuhiro Asami, Tomonori Hirashima, Norio Okamoto, Tadahiro Yamadori, Motohiro Tamiya, Naoko Morishita, Takayuki Shiroyama, Sawa Takeoka, Akio Osa and 5 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Lung, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hidekazu SuzukiDepartment of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, 3-7-1 Habikino Habikino-shi, Osaka, 583-8588, Japan, suzukih@opho.jp.
Kazuhiro Asami
Tomonori Hirashima
Norio Okamoto
Tadahiro Yamadori
Motohiro Tamiya
Naoko Morishita
Takayuki Shiroyama
Sawa Takeoka
Akio Osa
Yuichiro Azuma
Kyoichi Okishio
Tomoya Kawaguchi
Shinji Atagi
Ichiro Kawase

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposePrognostic factors and complicated prognostic models have been proposed for malignant pleural mesothelioma (MPM). This study was designed to stratify MPM prognosis by using a simple model.

methodsPatients diagnosed with MPM in the past 10 years (n = 122) were examined retrospectively. Data on the presence of chest pain, performance status (PS), asbestos exposure, smoking status, white blood cell count (WBC), haemoglobin (Hb) concentration, platelet count (PLT), lactate dehydronate (LD), histology, stage, and date of death or censored status were collected. After the factors were examined in the univariate analysis, recursive partitioning analysis was performed.

resultsStatistically significant factors related to survival were the type of histology, stage, PS, WBC, PLT, Hb concentration, and LD. Histology, stage, PS, and Hb concentration were used in multivariate analysis. Stage and Hb concentration showed good statistical significance, whereas PS was borderline significant. The survival analyses were stratified into five groups by PS, stage, Hb concentration, and chest pain using recursive partitioning analysis. Group A comprised patients showing the most favourable prognoses (PS 0-2 and Hb concentration >12.1 g dL(-1) or PS 0-2 and Hb concentration ≤12.1 g dL(-1) without pain), and group B comprised the remaining patients. The median overall survival in groups A and B was 563 days (95 % confidence interval [CI] 502-779) and 157 days (95 % CI 115-224), respectively (hazard ratio of 5.44 [3.46-8.53, P < 0.0001]).

conclusionsThe MPM patients with PS 0-2 and Hb concentration >12.1 or ≤12.1 g dL(-1) without chest pain had favourable prognoses.

Indexed as

Decision Support TechniquesAgedAlgorithmsAsbestosBiomarkersChest PainFemaleHemoglobinsHumansJapanKaplan-Meier EstimateLeukocyte CountL-Lactate DehydrogenaseLung NeoplasmsMaleMesotheliomaAsbestosBiomarkersHemoglobinsL-Lactate Dehydrogenase

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.